Risk scores designed for pulmonary arterial hypertension (Group I of the World Health Organisation classification for pulmonary hypertension) do not adequately account for the unique pathophysiology seen in patients whose pulmonary hypertension arises from underlying lung disease (Group III of the World Health Organisation (WHO) classification). This is the rationale behind a retrospective study of 793 patients with pulmonary hypertension due to lung disease, investigating a new risk assessment tool, the PVD-B65 score, to see if it has the potential to address this important gap.
Findings reveal that the PVD-B65 score was able to stratify patients into low, intermediate, or high risk for mortality. The tool achieved internal validation and offers clinicians a practical, scalable way to improve prognostication, guide decisions on referrals, and enhance patient discussions. However, external validation across broader cohorts is still needed for further confirmation.
Read more at this link on Healio